Fortress Biotech, Inc. (FBIO) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Fortress Biotech reported revenue of $63.3M, up 9.7% from $57.7M the year before. Net income was $6.8M (a 10.8% net margin), or -$0.07 per diluted share. Gross margin was 66.9% and operating margin was -111.0%. Operating activities generated -$65.8M of cash. At fiscal year end, Fortress Biotech held $185.5M in total assets against $123.4M in total liabilities, including $79.4M of cash and equivalents.
Open the full interactive Fortress Biotech financials → Quarterly statements, key ratios, valuation history and price charts.
Fortress Biotech Key Stats
| Share Price | $1.95 |
|---|---|
| Market Cap | $62.0M |
| Revenue YoY Growth | +9.7% |
| 52-Week Range | $1.95 – $4.38 |
| Shares Outstanding | 31.8 million (basic, 2026 Q2) |
Fortress Biotech Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $45.6M | $68.8M | $75.7M | $84.5M | $57.7M | $63.3M |
| Cost of Goods Sold | $14.6M | $32.1M | $30.8M | $26.7M | $20.9M | $20.9M |
| Gross Profit | $31.0M | $36.7M | $45.0M | $57.9M | $36.8M | $42.3M |
| Operating Income | -$94.3M | -$188.5M | -$203.6M | -$142.3M | -$110.4M | -$70.2M |
| Pre-Tax Income | -$102.8M | -$164.4M | -$213.5M | -$153.6M | -$120.5M | -$33.5M |
| Income Tax | $136,000 | $473,000 | $449,000 | $521,000 | $312,000 | -$620,000 |
| Net Income | -$46.5M | -$64.7M | -$86.6M | -$60.6M | -$46.0M | $6.8M |
| Diluted EPS | -$9.75 | -$11.85 | -$14.55 | -$8.47 | -$2.69 | -$0.07 |
Fortress Biotech Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $17.6M | $16.1M | $16.0M | $18.7M |
| Net Income | $5.8M | -$3.9M | $110.4M | -$468,000 |
| Diluted EPS | $0.11 | -$0.14 | $2.82 | -$0.08 |
Fortress Biotech Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $233.4M | $305.7M | $178.3M | $80.9M | $57.3M | $79.4M |
| Current Assets | $261.6M | $346.5M | $230.4M | $117.0M | $90.4M | $123.8M |
| Total Assets | $328.8M | $396.5M | $294.3M | $167.5M | $144.2M | $185.5M |
| Current Liabilities | $48.0M | $101.0M | $127.7M | $84.9M | $71.4M | $49.7M |
| Total Long-Term Debt | $51.7M | $42.9M | $91.7M | $60.9M | $58.0M | $52.4M |
| Total Liabilities | $131.8M | $170.6M | $244.3M | $165.9M | $145.9M | $123.4M |
| Shareholders' Equity | $100.3M | $108.7M | $41.7M | $22.5M | $22.7M | $49.9M |
Fortress Biotech Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$83.7M | -$116.5M | -$179.4M | -$128.2M | -$80.2M | -$65.8M |
| Cash From Investing | -$7.2M | $40.5M | -$22.9M | -$2.1M | -$15.0M | $10.1M |
| Cash From Financing | $172.4M | $149.0M | $75.3M | $32.7M | $70.6M | $77.4M |
| Free Cash Flow | -$85.6M | -$121.1M | -$182.1M | -$128.3M | -$80.2M | — |
Figures from Fortress Biotech's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Fortress Biotech financials page for every line item.
Fortress Biotech Company Profile
| Ticker | FBIO |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Bay Harbor Islands, Florida |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001429260 |
Frequently Asked Questions
What was Fortress Biotech's revenue in fiscal 2025?
Fortress Biotech (FBIO) reported revenue of $63.3M for fiscal 2025.
What is Fortress Biotech's annual revenue history?
Fortress Biotech's annual revenue by fiscal year: 2020: $45.6M; 2021: $68.8M; 2022: $75.7M; 2023: $84.5M; 2024: $57.7M; 2025: $63.3M.
What was Fortress Biotech's net income in fiscal 2025?
Fortress Biotech reported net income of $6.8M for fiscal 2025.
What was Fortress Biotech's earnings per share (EPS) in fiscal 2025?
Fortress Biotech's diluted EPS was -$0.07 for fiscal 2025 (adjusted for any later stock splits).
What was Fortress Biotech's revenue last quarter?
In its most recent reported quarter (2026 Q2), Fortress Biotech reported revenue of $18.7M.
How much debt does Fortress Biotech have?
Fortress Biotech reported $52.4M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Fortress Biotech are outstanding?
Fortress Biotech reported a weighted average of 31.8 million basic shares outstanding in 2026 Q2.
What is Fortress Biotech's market cap?
Based on its latest closing price, Fortress Biotech (FBIO) has a market capitalization of about $62.0M.
When does Fortress Biotech's fiscal year end?
Fortress Biotech's fiscal year end, as registered with the SEC, is December 31.
Where is Fortress Biotech headquartered?
Fortress Biotech lists its business address in Bay Harbor Islands, Florida in its SEC filings.